BACKGROUND AND OBJECTIVES: Use of incompatible kidney transplantation (IKT) is growing as a response to the organ shortage and the increase in sensitization among candidates. However, recent regulatory mandates possibly threaten IKT, and the potential effect of these mandates cannot be estimated because dissemination of this modality remains unknown. The goal of this study was to better understand practice patterns of IKT in the United States. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Directors from all 187 unique active adult kidney transplant programs were queried about transplantation across the following antibody barriers: positive Luminex, negative flow crossmatch (PLNF); positive flow, negative cytotoxic crossmatch (PFNC); positive cytotoxic crossmatch (PCC); and ABO incompatible (ABOi). RESULTS: Responses from 125 centers represented 84% of the live-donor transplant volume in the United States. Barriers of PLNF, PFNC, PCC, and ABOi are being crossed in 70%, 51%, 18%, and 24%, respectively, of transplant centers that responded. Desensitization was performed in 58% of PLNF, 76% of PFNC, 100% of PCC, and 80% of ABOi using plasmapheresis and low-dose intravenous Ig (IVIg) in 71% to 83% and high-dose IVIg in 29% to 46%. CONCLUSIONS: A higher proportion of centers perform IKT than might be inferred from the literature. The rapid dissemination of these protocols despite adequate evidence of a clear advantage of IKT transplants argues for the creation of a national registry and randomized studies.
BACKGROUND AND OBJECTIVES: Use of incompatible kidney transplantation (IKT) is growing as a response to the organ shortage and the increase in sensitization among candidates. However, recent regulatory mandates possibly threaten IKT, and the potential effect of these mandates cannot be estimated because dissemination of this modality remains unknown. The goal of this study was to better understand practice patterns of IKT in the United States. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Directors from all 187 unique active adult kidney transplant programs were queried about transplantation across the following antibody barriers: positive Luminex, negative flow crossmatch (PLNF); positive flow, negative cytotoxic crossmatch (PFNC); positive cytotoxic crossmatch (PCC); and ABO incompatible (ABOi). RESULTS: Responses from 125 centers represented 84% of the live-donor transplant volume in the United States. Barriers of PLNF, PFNC, PCC, and ABOi are being crossed in 70%, 51%, 18%, and 24%, respectively, of transplant centers that responded. Desensitization was performed in 58% of PLNF, 76% of PFNC, 100% of PCC, and 80% of ABOi using plasmapheresis and low-dose intravenous Ig (IVIg) in 71% to 83% and high-dose IVIg in 29% to 46%. CONCLUSIONS: A higher proportion of centers perform IKT than might be inferred from the literature. The rapid dissemination of these protocols despite adequate evidence of a clear advantage of IKT transplants argues for the creation of a national registry and randomized studies.
Authors: Robert A Montgomery; Sommer E Gentry; William H Marks; Daniel S Warren; Janet Hiller; Julie Houp; Andrea A Zachary; J Keith Melancon; Warren R Maley; Hamid Rabb; Christopher Simpkins; Dorry L Segev Journal: Lancet Date: 2006-07-29 Impact factor: 79.321
Authors: Stanley C Jordan; Dolly Tyan; Don Stablein; Matthew McIntosh; Steve Rose; Ashley Vo; Mieko Toyoda; Connie Davis; Ron Shapiro; Deborah Adey; Dawn Milliner; Ralph Graff; Robert Steiner; Gaetano Ciancio; Shobah Sahney; Jimmy Light Journal: J Am Soc Nephrol Date: 2004-12 Impact factor: 10.121
Authors: Andrea A Zachary; Robert A Montgomery; Lloyd E Ratner; Millie Samaniego-Picota; Mark Haas; Dessislava Kopchaliiska; Mary S Leffell Journal: Transplantation Date: 2003-11-27 Impact factor: 4.939
Authors: Francis L Delmonico; Paul E Morrissey; George S Lipkowitz; Jeffrey S Stoff; Jonathan Himmelfarb; William Harmon; Martha Pavlakis; Helen Mah; Jane Goguen; Richard Luskin; Edgar Milford; Giacomo Basadonna; Michael Chobanian; Beth Bouthot; Marc Lorber; Richard J Rohrer Journal: Am J Transplant Date: 2004-10 Impact factor: 8.086
Authors: Margaux N Mustian; Robert M Cannon; Paul A MacLennan; Rhiannon D Reed; Brittany A Shelton; Deanna M McWilliams; Mark H Deierhoi; Jayme E Locke Journal: J Am Coll Surg Date: 2018-01-05 Impact factor: 6.113
Authors: Courtenay M Holscher; Kyle Jackson; Alvin G Thomas; Christine E Haugen; Sandra R DiBrito; Karina Covarrubias; Sommer E Gentry; Matthew Ronin; Amy D Waterman; Allan B Massie; Jacqueline Garonzik Wang; Dorry L Segev Journal: Am J Transplant Date: 2018-09-12 Impact factor: 8.086
Authors: Kyle J Van Arendonk; Nathan T James; Babak J Orandi; Jacqueline M Garonzik-Wang; Jodi M Smith; Paul M Colombani; Dorry L Segev Journal: Transplantation Date: 2013-09-15 Impact factor: 4.939
Authors: Krista L Lentine; David Axelrod; Christina Klein; Christopher Simpkins; Huiling Xiao; Mark A Schnitzler; Janet E Tuttle-Newhall; Vikas R Dharnidharka; Daniel C Brennan; Dorry L Segev Journal: Transplantation Date: 2014-07-15 Impact factor: 4.939